Head-to-head evidence
bb21217 vs Idecabtagene vicleucel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
bb21217
Developed by 2seventy bio, Inc. (wholly-owned subsidiary of Bristol Myers Squibb)
NCT03274219 · Phase 1 · completed
There was no control group and no blinding: everyone in the study received bb21217, and the trial was designed to check safety rather than measure effectiveness. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Idecabtagene vicleucel
Marketed by Bristol-Myers Squibb
NCT03651128 · Phase 3 · completed
Randomized, open-label Phase 3 trial (n=386) demonstrating significant improvement in PFS vs standard regimens in relapsed/refractory multiple myeloma (NEJM 2023).
Next expected readout: May 2027 · NCT05393804 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bb21217's landscape · Idecabtagene vicleucel's landscape